Integrated Network Pharmacology and UPLC/Q-TOF-MS Screen System to Exploring Anti-Inflammatory Active Components and Mechanism of Shunaoxin Pills

Figure 4

Network pharmacology analysis of the active components of SNX. (a) The 18 overlapping targets between the CCI and anti-inflammatory active compounds of SNX. (b) The PPI network of 18 overlapping targets. (c) The KEGG pathway enrichment analysis of 18 overlapping targets and the top 10 significantly enriched inflammation-related pathways.

(a)

(b)

(c)